Eli Lilly has a Fever, and the only prescription is a new corporate partnership. | Eli Lilly has a Fever, and the only ...

Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...

Preeclampsia, a pregnancy complication typically associated with high blood pressure, is estimated to affect around one in ...

As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...

Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be ...

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the ...

Amid a U.S. biosecurity crackdown targeting certain Chinese manufacturers and contract research organizations, production ...

The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with ...

While an ongoing production expansion push for Eli Lilly's popular tirezeptide-based medicines Mounjaro and Zepbound should ...

It’s no secret that U.S. biopharma companies rely on Chinese contractors to provide lab research and drug manufacturing ...